Amgen reported strong Q4 and full-year results, with revenues and EPS exceeding expectations and positive guidance for 2014. Management highlighted a robust pipeline with significant upcoming data readouts, successful acquisitions like Onyx, and accelerated international expansion. The confident tone and promising developments suggest a positive short-term impact on the stock price.

[1]